IRIS
FANIN, Renato
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 27.752
AS - Asia 10.942
EU - Europa 7.644
SA - Sud America 2.202
Continente sconosciuto - Info sul continente non disponibili 1.106
AF - Africa 267
OC - Oceania 13
Totale 49.926
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 27.336
SG - Singapore 5.032
CN - Cina 2.389
UA - Ucraina 2.123
BR - Brasile 1.720
DE - Germania 1.133
HK - Hong Kong 1.127
IT - Italia 918
VN - Vietnam 801
FI - Finlandia 798
RU - Federazione Russa 594
FR - Francia 518
SE - Svezia 518
IE - Irlanda 386
IN - India 259
CA - Canada 252
TR - Turchia 242
GB - Regno Unito 240
BD - Bangladesh 235
AR - Argentina 173
KR - Corea 170
IQ - Iraq 114
MX - Messico 83
CO - Colombia 81
ZA - Sudafrica 81
ID - Indonesia 71
PL - Polonia 68
EC - Ecuador 63
PK - Pakistan 63
JP - Giappone 52
ES - Italia 49
NL - Olanda 49
UZ - Uzbekistan 45
AT - Austria 44
IR - Iran 43
VE - Venezuela 38
SA - Arabia Saudita 36
MA - Marocco 35
CZ - Repubblica Ceca 34
CL - Cile 31
PY - Paraguay 31
PE - Perù 28
AE - Emirati Arabi Uniti 26
MY - Malesia 26
BE - Belgio 25
KE - Kenya 25
PH - Filippine 25
EG - Egitto 23
KZ - Kazakistan 20
TG - Togo 20
IL - Israele 19
TN - Tunisia 19
EU - Europa 18
JO - Giordania 18
RO - Romania 18
UY - Uruguay 18
BO - Bolivia 17
NP - Nepal 17
LT - Lituania 16
JM - Giamaica 15
GR - Grecia 14
RS - Serbia 14
ET - Etiopia 13
KG - Kirghizistan 13
OM - Oman 13
TH - Thailandia 13
TT - Trinidad e Tobago 13
AU - Australia 12
AL - Albania 11
AZ - Azerbaigian 10
CH - Svizzera 10
LB - Libano 10
CR - Costa Rica 9
DZ - Algeria 9
LV - Lettonia 9
PS - Palestinian Territory 9
PT - Portogallo 9
DO - Repubblica Dominicana 8
GE - Georgia 8
NI - Nicaragua 8
BG - Bulgaria 7
BH - Bahrain 6
HU - Ungheria 6
LK - Sri Lanka 6
AO - Angola 5
GA - Gabon 5
GT - Guatemala 5
HN - Honduras 5
LU - Lussemburgo 5
PA - Panama 5
RW - Ruanda 4
TW - Taiwan 4
BY - Bielorussia 3
EE - Estonia 3
HR - Croazia 3
KH - Cambogia 3
KW - Kuwait 3
LY - Libia 3
MD - Moldavia 3
NO - Norvegia 3
Totale 48.770
Salva come PNG Salva come JPEG
Città #
Fairfield 2.992
Woodbridge 2.896
Ashburn 2.048
Houston 1.998
Singapore 1.931
Ann Arbor 1.893
Jacksonville 1.420
Seattle 1.228
Beijing 1.170
Wilmington 1.132
Hong Kong 1.119
Chandler 1.109
San Jose 1.049
Cambridge 981
Dearborn 891
Boardman 525
Council Bluffs 404
Dublin 384
Princeton 383
Dallas 381
Lauterbourg 375
Los Angeles 333
Udine 283
Ho Chi Minh City 250
Buffalo 202
San Diego 189
Hefei 179
Santa Clara 175
Izmir 170
Hanoi 159
New York 158
São Paulo 158
Seoul 153
Munich 129
Helsinki 118
Redondo Beach 111
Ogden 101
Ottawa 99
Norwalk 87
The Dalles 87
Des Moines 84
Dong Ket 84
Frankfurt am Main 70
Trieste 67
Orem 64
Warsaw 61
Montreal 59
Turku 56
Nanjing 55
Milan 54
Rio de Janeiro 54
Mumbai 53
Redmond 50
Toronto 48
Tokyo 46
Phoenix 43
Pittsburgh 43
Atlanta 42
Nuremberg 42
Kunming 41
Baghdad 40
Chennai 40
Tashkent 40
London 39
Chicago 36
Johannesburg 36
Belo Horizonte 34
Guangzhou 33
Stockholm 32
Da Nang 31
Rome 31
Denver 29
Regensburg 29
Simi Valley 29
Boston 28
Brasília 28
Dhaka 28
Haiphong 28
Brooklyn 27
Curitiba 27
Poplar 27
Jinan 25
Mexico City 25
Brussels 24
Porto Alegre 24
Hangzhou 23
Nanchang 23
Quito 23
Shanghai 23
Amsterdam 21
Guayaquil 21
Nairobi 21
Saint Petersburg 21
Vienna 21
Bogotá 20
Düsseldorf 20
Leawood 20
Manchester 20
San Francisco 20
Campinas 19
Totale 31.652
Salva come PNG Salva come JPEG
Nome #
Prognostic significance of the detection of tumour cells in peripheral blood stem cell collections in stage II and III breast cancer patients treated with high-dose therapy 281
Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party 242
BAALC overexpression retains its negative prognostic role across all cytogenetic risk groups in acute myeloid leukemia patients 226
Activity of all-trans-retinoic acid in a case of central nervous system extramedullary relapse of acute promyelocytic leukemia 212
Abdominal abscess and Hafnia alvei septicemia occurring during the aplastic phase after autologous stem-cell transplantation in a patient with diffuse large B-cell lymphoma. 210
Clinical impact of CD200 expression in patients with acute myeloid leukemia and correlation with other molecular prognostic factors 209
Adjuvant treatment with cyclosporin A increases the toxicity of chemotherapy for remission induction in acute non-lymphocytic leukemia. 207
Fludarabine-based induction therapy does not overcome the negative effect of ABCG2 (BCRP) over-expression in adult acute myeloid leukemia patients. 205
Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases 201
Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO)” 198
Decreased function of Fas and variations of the perforin gene in adult patients with primary immune thrombocytopenia 197
Central nervous system fungal infections in allogeneic stem cell transplantation. Outcome of 24 recent cases and literature review 197
Allogeneic hematopoietic cell transplantation from unrelated donors in multiple myeloma: study from the Italian Bone Marrow Donor Registry. 193
Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia. 193
Atypical haemolytic-uraemic syndrome at the onset of acute promyelocytic leukaemia. 191
A sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia: final results of the GIMEMA LAL 0904 study 191
Antifungal prophylaxis with posaconazole in patients with acute myeloid leukemia: dose intensification coupled with avoidance of proton pump inhibitors is beneficial in shortening time to effective concentrations. 189
The development of autoantibodies after allogeneic stem cell transplantation is related with chronic graft-vs-host disease and immune recovery 188
Co-administration of proton pump inhibitors and/or of steroids may be a risk factor for low trough concentrations of posaconazole delayed-released tablets in adult patients with hematological malignancies 187
Multipotent Progenitor Cells Are Present in Human Peripheral Blood. 184
Low-dose rituximab in adult patients with primary immune thrombocytopenia. 183
B-cell immune reconstitution after allogenic stem cell transplantation and its role in the development of chronic graft-versus-host disease 182
Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years 182
ABCG2, Cytogenetics, and Age Predict Relapse after Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in Complete Remission 182
Efficacy and safety of rituximab in type II mixed cryoglobulinemia. 179
The role of positron emission tomography with 18F-fluorodeoxyglucose integrated with computed tomography in the evaluation of patients with multiple myeloma undergoing allogeneic stem cell transplantation 179
A phase II study of α-interferon and oral arabinosyl cytosine (YNK01) in chronic myeloid leukemia 179
Allogeneic stem cell transplantation in multiple myeloma relapsed after autograft: A multicenter retrospective study based on donor availability 179
A comparison of allografting with autografting for newly diagnosed myeloma 178
Multidrug resistance modulation in vivo: the effect of cyclosporin A alone or with dexverapamil on idarubicin pharmacokinetics in acute leukemia. 178
ABCG2 overexpression and deoxyadenosine analogue activity in acute myeloid leukemia 178
P-glycoprotein (PGP) and lung resistance-related protein (LRP) expression and function in leukaemic blast cells 177
P-glycoprotein, lung resistance-related protein and multidrug resistance-associated protein in de novo adult acute lymphoblastic leukaemia. 176
Efficacy and safety of rituximab in type II mixed cryoglobulinemia 175
Differences among young adults, adults and elderly chronic myeloid leukemia patients. 174
Aberrant expression of TRAIL in B chronic lymphocytic leukemia (B-CLL) cells. 174
ABCG2 overexpression in patients with acute myeloid leukemia: Impact on stem cell transplantation outcome 173
Rituximab in immune thrombocytopenia: gender, age, and response as predictors of long-term response. 173
Multipotent Mesenchymal Stem Cells Can Be Isolated and Grown from Many Tissues (Bone Marrow, Liver and Heart) 173
Predictive value of pretransplantation molecular minimal residual disease assessment by WT1 gene expression in FLT3-positive acute myeloid leukemia 170
Family history of cancer and risk of second malignancies in young cancer patients in Trieste, Italy. 169
Nilotinib and donor lymphocyte infusion in the treatment of Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) relapsing after allogeneic stem cell transplantation and resistant to imatinib 169
Impact of hepatitis C virus infection on clinical features, quality of life and survival of patients with lymphoplasmacytoid lymphoma/immunocytoma 169
JAK-2 inhibitors and allogeneic transplant in myelofibrosis 169
Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study 168
Prognostic factors and outcome of Epstein-Barr virus DNAemia in high-risk recipients of allogeneic stem cell transplantation treated with preemptive rituximab. 168
Management of immune thrombocytopenia in elderly patients 168
Earlier administration of Rituximab allows higher rate of long-lasting response in adult patients with autoimmune thrombocytopenia 167
High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission 166
BCL-2 immunohistochemical evaluation in B-cell chronic lymphocytic leukemia and hairy cell leukemia before treatment with fludarabine and 2-chloro-deoxy-adenosine 165
Fludarabine: an active agent in the treatment of previously-treated and untreated low-grade non-Hodgkin's lymphoma. 164
Variability of Voriconazole Trough Levels in Haematological Patients: Influence of Comedications with cytochrome P450(CYP) Inhibitors and/or with CYP Inhibitors plus CYP Inducers. 164
ABCG2 and CD200 define patients at high risk of relapse in ELN favorable subgroup of AML 162
Acute hepatic failure as onset of progressive sclerodermatous chronic graft-versus-host disease after donor lymphocyte infusion. 162
Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia 161
Granulocyte colony-stimulating factor (G-CSF) allows the delivery of effective doses of CHOP and CVP regimens in non-Hodgkin lymphomas. 161
Autologus stem cell transplantation as postremission therapy for acute myeloid leukemia. Risk factors at diagnosis can predict the outcome. 159
“Overexpression of multidrug resistance-associated P-170 glycoprotein in acute non lymphocytic leukemia”. 159
Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long-term follow-up results 159
Quality of life in elderly patients with essential thrombocythaemia. An Italian multicentre study. 158
Donor compatibility and performance status affect outcome of allogeneic haematopoietic stem cell transplant in patients with relapsed or refractory acute myeloid leukaemia 158
Rituximab for the treatment of type II mixed cryoglobulinemia. 157
Efficacy and toxicity of Decitabine in patients with acute myeloid leukemia (AML): A multicenter real-world experience 157
Population pharmacokinetics and pharmacodynamic target attainment of isavuconazole against aspergillus fumigatus and aspergillus flavus in adult patients with invasive fungal diseases: Should therapeutic drug monitoring for isavuconazole be considered as mandatory as for the other mold-active azoles? 157
Autologous stem cell transplantation in chronic carriers of hepatitis B virus and hepatitis C virus affected by onco-hematologic diseases. 156
A Comparison of the Conditioning Regimens BEAM and FEAM for Autologous Hematopoietic Stem Cell Transplantation in Lymphoma: An Observational Study on 1038 Patients From Fondazione Italiana Linfomi 156
Allogeneic hematopoietic stem cell transplantation in patients with diffuse large B cell lymphoma relapsed after autologous stem cell transplantation: a GITMO study. 155
Best practice recommendations in: (1) Peripheral blood stem cell mobilization and collection and (2) acute and chronic GvHD treatment using extracorporeal photopheresis. A joint effort from SIdEM (Società Italiana di Emaferesi e Manipolazione Cellulare) and GITMO (Gruppo Italiano Trapianto di Midollo Osseo). 155
Late onset cytomegalovirus encephalitis after reduced-intensity conditioning allogeneic SCT: an emerging neurological complication? 155
B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia. 155
Risk Factors and Outcomes of Infections by Multidrug-Resistant Gram-Negative Bacteria in Patients Undergoing Hematopoietic Stem Cell Transplantation 155
Long-Term Follow-Up of a Donor versus No-Donor Comparison in Patients with Multiple Myeloma in First Relapse after Failing Autologous Transplantation 155
Busulfan- or Thiotepa-Based Conditioning in Myelofibrosis: A Phase II Multicenter Randomized Study from the GITMO Group 155
Brain natriuretic peptide level as marker of cardiac function in imatinib--treated chronic myeloid leukemia patients: no evidence of cardiotoxicity of imatinib therapy. 154
Treatment of elderly patients (> or =60 years) with newly diagnosed acute promyelocytic leukemia. Results of the Italian multicenter group GIMEMA with ATRA and idarubicin (AIDA) protocols. 154
Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi 154
Acute promyelocytic leucemia: low expression of multidrug resistance phenotype at onset suggest a favourable effect of gentuzumab ozogamicyn (CMA-676 153
Unexpected phenotype of a typical NPM1 mutant 153
Nonpermissive HLA-DPB1 disparity is a significant independent risk factor for mortality after unrelated hematopoietic stem cell transplantation 152
Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index: a prospective, multicenter GITMO study. 152
Pre-Chemotherapy risk factors for invasive fungal diseases: Prospective analysis of 1,192 patients with newly diagnosed acute myeloid leukemia (seifem 2010-a multicenter study) 152
Longitudinal follow-up of WT1 gene expression as monitoring of minimal residual disease in acute myeloid leukemia following allogeneic bone marrow transplant 151
Granulocyte-macrophage colony -stimulating factor in acute nonlymphocytic leukemia before and after chemo therapy”. 151
Bendamustine in chronic lymphocytic leukemia: Outcome according to different clinical and biological prognostic factors in the everyday clinical practice. 151
EUTOS score predicts long-term outcome but not optimal response to imatinib in patients with chronic myeloid leukaemia. 151
Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura 150
Purging of chronic myelogenous leukemia cells by retrovirally expressed anti-bcr-abl ribozymes with specific cellular compartmentalization. 149
A simple Prognostic Scoring System for newly diagnosed acute leukaemia patients with normal karyotype: a retrospective analysis on 173 cases. 149
CONCOMITANT BCRP OVER-EXPRESSION AND FLT3-ITD MUTATION IDENTIFY A SUBSET OF ACUTE MYELOID LEUKEMIA PATIENTS AT HIGH RISK OF RELAPSE 149
Excellent outcomes of 2G-TKI therapy after imatinib failure in chronic phase CML patients 149
Response rate and survival after thalidomide-based therapy in 248 patients with myelodysplastic syndromes. 148
Multidrug resistance modulation in vivo. The effect of cyclosporin alone or with dextro-verapamil on idarubicin pharmacokinetics in acute leukemia 148
Clinical factors predictive of myelofibrotic evolution in patients with polycythemia vera. 147
Allogeneic stem cell transplantation and novel therapies: is the treatment paradigm for younger patients with chronic lymphocytic leukemia changing? 147
Risk of sinusoidal obstruction syndrome in allogeneic stem cell transplantation after prior gemtuzumab ozogamicin treatment: A retrospective study from the Acute Leukemia Working Party of the EBMT 147
Incidence of bacterial and fungal infections in newly diagnosed acute myeloid leukaemia patients younger than 65 years treated with induction regimens including fludarabine: retrospective analysis of 224 cases 146
KIR POLYMORPHISM IN REDUCED INTENSITY HLA-ID SIBLING STEM CELL TRANSPLANTATION: IMPACT ON CLINICAL OUTCOME 146
Efficacy of selective B cell Blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells 146
CHOP-rituximab with pegylated liposomal doxorubicin for the treatment of elderly patients with diffuse large B-cell lymphoma 146
Long-term efficacy and safety of nilotinib therapy after imatinib failure in eosinophilic myeloproliferative neoplasm and ETV6-ABL rearrangement 146
Totale 16.999
Salva come PNG Salva come JPEG
Categoria #
all - tutte 187.555
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 187.555
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.983 0 364 156 225 93 144 185 143 56 507 634 476
2022/20232.817 419 159 31 328 259 829 14 207 384 37 86 64
2023/2024853 122 66 27 27 132 100 17 53 142 65 32 70
2024/20256.868 149 502 381 170 292 309 407 426 665 603 1.093 1.871
2025/202613.484 1.008 1.468 1.119 1.335 1.865 1.070 1.584 436 1.010 1.271 809 509
2026/2027344 340 4 0 0 0 0 0 0 0 0 0 0
Totale 49.926